IDEXX Laboratories, Inc. $IDXX Stock Holdings Decreased by Ritholtz Wealth Management

Ritholtz Wealth Management lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 912 shares of the company’s stock after selling 36 shares during the period. Ritholtz Wealth Management’s holdings in IDEXX Laboratories were worth $489,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $29,000. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at about $26,000. Ameritas Advisory Services LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after buying an additional 30 shares during the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at about $37,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director owned 262 shares in the company, valued at $169,600.46. This represents a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 0.3%

Shares of NASDAQ:IDXX opened at $635.40 on Monday. The company has a 50 day moving average of $639.99 and a 200-day moving average of $551.18. The firm has a market cap of $50.83 billion, a P/E ratio of 52.91, a P/E/G ratio of 4.11 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the business earned $2.44 earnings per share. The business’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective for the company. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. Finally, Piper Sandler restated a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.